BLINATUMOMAB

Information current as at: 1 June 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Blincyto
Form and strength:

Please search for and view the meeting agenda from the relevant meeting for more information

Submission sponsor:
Amgen Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Acute lymphoblastic leukaemia (ALL) Precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)
Listing requested:
Please see meeting agenda for more information
Funding program:
Please see meeting agenda for more information
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
Change to listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
December 2025 PBAC meeting
Opportunity for consumer comment:
--
PBAC meeting:
Held on 10/12/2025
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
12/03/2026
Lodgement of required documentation:
19/03/2026
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 02/04/2026
Status:
Finalised
Government processes:
Commenced on 02/04/2026
Medicine listed on the PBS:
01/06/2026 (see PBS schedule)
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – December 2025
Case ID
a1195
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19